Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HUMANA INCHUM · Entity 1429 | Director | September 30, 2026 | October 02, 2026 |
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director | May 26, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HUMANA INC
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,772 |
Reported balance
After 2026-09-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-30 · Grant · Acquired 238 · Balance 16,772 F3: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,800 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 24,800 F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,364 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,364 F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). |
| Humana CommonSEC Table I · non-derivative | Direct | 19,448 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 19,448 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.
F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F3: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election.
Outlook Therapeutics, Inc.
Report date May 26, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 423,655 |
Reported balance
After 2026-05-26 transaction · row 1
1 source rowRow 1 · 2026-05-26 · Purchase · Acquired 400,000 · Balance 423,655 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2018 Filed Dec 28, 2018 22:06 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 5,714 | $0.54 | $3,085.56 |
DisclosureSEC source: 0001209191-18-064336 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,227 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4759 - $0.5950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 22:17 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 1,113 | $0.66 | $734.58 |
DisclosureSEC source: 0001209191-18-064123 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,513 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.65 - $0.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 22:17 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 3,600 | $0.65 | $2,340.00 |
DisclosureSEC source: 0001209191-18-064123 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63 - $0.6706, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes an aggregate of 7,246 shares that were issued upon vesting and settlement of Restricted Stock Units previously reported in a Form 3 filed with the Securities and Exchange Commission on May 12, 2016 but erroneously omitted from Column 5 in subsequent filings. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:56 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 203,851 | $0.61 Strike: $0.89 | $124,960.66 |
DisclosureSEC source: 0001209191-18-058304 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,851 Underlying: Common Stock · 203,851 shares Expires 2028-11-09 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Plan in lieu of two years of cash retainer and meeting fees of $125,000. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 15:22 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 254 | $336.65 | $85,509.10 |
DisclosureSEC source: 0000049071-18-000119 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,059 Underlying: Humana Common · 254 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:59 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001209191-18-052158 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-09-21 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on September 21, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 15:08 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 280 | $299.02 | $83,725.60 |
DisclosureSEC source: 0000049071-18-000095 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,805 Underlying: Humana Common · 280 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 16:16 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 311 | $267.24 | $83,111.64 |
DisclosureSEC source: 0000049071-18-000059 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,525 Underlying: Humana Common · 311 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 20:57 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000004 · edgar.xml · derivative · entry 5 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658 Underlying: Humana Common · 658 shares Expires not disclosed F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 20:57 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 346 | $249.45 | $86,309.70 |
DisclosureSEC source: 0000049071-18-000004 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,214 Underlying: Humana Common · 346 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 20:57 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 173 | $249.45 | $43,154.85 |
DisclosureSEC source: 0000049071-18-000004 · edgar.xml · derivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862 Underlying: Humana Common · 173 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 22:07 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-17-058366 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-10-26 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 17:34 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 355 | $242.26 | $86,000.53 |
DisclosureSEC source: 0000049071-17-000166 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,868 Underlying: Humana Common · 355 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:57 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 318 | $240.77 | $76,564.86 |
DisclosureSEC source: 0000049071-17-000138 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,513 Underlying: Humana Common · 318 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:21 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 371 | $206.42 | $76,581.82 |
DisclosureSEC source: 0000049071-17-000092 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,195 Underlying: Humana Common · 371 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| January 23, 2017 Filed Jan 24, 2017 22:44 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | OtherWarrant (Right to Buy) · Derivative | 12,036 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001209191-17-005333 · doc4.xml · derivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,036 shares Expires 2019-11-08 F1 · kind: Represents the exercise of (i) a Warrant to purchase 7,561 received from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 received from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 23, 2017 Filed Jan 24, 2017 22:44 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | OtherCommon Stock | 12,036 | $0.01 | $120.36 |
DisclosureSEC source: 0001209191-17-005333 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,554 F1 · kind: Represents the exercise of (i) a Warrant to purchase 7,561 received from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 received from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:38 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 761 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000006 · edgar.xml · derivative · entry 5 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761 Underlying: Humana Common · 761 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2017. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2017. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2017. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:38 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 376 | $203.53 | $76,527.28 |
DisclosureSEC source: 0000049071-17-000006 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,824 Underlying: Humana Common · 376 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:38 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 144 | $203.53 | $29,308.32 |
DisclosureSEC source: 0000049071-17-000006 · edgar.xml · derivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689 Underlying: Humana Common · 144 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| November 30, 2016 Filed Nov 30, 2016 22:25 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | OtherCommon Stock | 6,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152513 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,518 F2 · kind: Represents the receipt of 6,885 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member. F2 · shares: Represents the receipt of 6,885 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member. F2 · price: Represents the receipt of 6,885 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member. Read SEC document |
| November 28, 2016 Filed Nov 30, 2016 22:25 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | OtherWarrant (Right to Buy) · Derivative | 12,036 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001209191-16-152513 · doc4.xml · derivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,036 Underlying: Common Stock · 12,036 shares Expires 2019-11-08 F3 · kind: Represents the receipt of (i) a Warrant to purchase 7,561 from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member, in a pro rata distribution for no consideration. F3 · shares: Represents the receipt of (i) a Warrant to purchase 7,561 from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member, in a pro rata distribution for no consideration. F4 · derivative.exercise_date: Immediately exercisable. F3 · derivative.underlying_shares: Represents the receipt of (i) a Warrant to purchase 7,561 from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member, in a pro rata distribution for no consideration. F3 · balance_after: Represents the receipt of (i) a Warrant to purchase 7,561 from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member, in a pro rata distribution for no consideration. Read SEC document |
| November 28, 2016 Filed Nov 30, 2016 22:25 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | OtherCommon Stock | 11,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152513 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,633 F1 · kind: Represents the receipt of 11,633 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · shares: Represents the receipt of 11,633 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · price: Represents the receipt of 11,633 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund LLC, of which the reporting person is a member. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 19:37 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 432 | $176.54 | $76,265.28 |
DisclosureSEC source: 0000049071-16-000174 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,448 Underlying: Humana Common · 432 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.